InSitu Biologics touted preclinical data for its non-opiate, hydrogel-based painkiller, AnestaGel, for use in peri-operative regional pain management. The St. Paul, Minn.-based company designs therapies using its Matrix biohydrogel material.
Independent tests compared operative site injections of AnestaGel and Pacira Pharmaceutical’s (NSDQ:PCRX) Exparel. According to InSitu, the data showed that AnestaGel lasted longer and provided a greater analgesic effect than Exparel. Another test showed that bupivacaine, the painkiller used in both AnestaGel and Exparel, was released from AnestaGel and stayed in the blood longer than Exparel and bupivacaine injections.
Get the full story at our sister site, Drug Delivery Business News.
The post InSitu Biologics touts preclinical data for non-opiate hydrogel painkiller appeared first on MassDevice.
from MassDevice http://ift.tt/2kkhJ4P
Cap comentari:
Publica un comentari a l'entrada